Pharmacological chaperones are small molecule synthetic compounds that induce the “correct” folding by binding to the protein and/or increase the target protein trafficking to cellular destination. Ultimately, pharmacological chaperones increase the cellular activity of the enzyme.
The first-generation pharmacological chaperones were competitive inhibitors of mutant enzymes. Allosteric chaperones are non-inhibitory ligands, targeting previously unknown binding pockets, limit the risk of adverse enzymatic inhibition. In ATLAS, the Chassys Platform is specially designed for the discovery and development of second-generation allosteric pharmacological chaperones.
Drug repurposing is meaningful in the context of rare and ultrarare diseases. Consequently, pharmacological chaperones developed in ATLAS embrace new chemical entities and repurposed drugs.
Parque Tecnológico de Bizkaia
Edificio 800, 48160 Derio (Bizkaia)
info@atlasmolecularpharma.com
+34 944061300 (ext. 4338)